NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
Estimated value
—
Awarded value
—
Suppliers
31
Lots
23
Published
11 Jun 2024
Description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024<br/><br/>Offer reference number: CM/PHS/22/5661<br/><br/>Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.<br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Scope
- Reference
- CM/PHS/22/5661
- Commercial tool
- Standalone contract
- Contract dates
- 30 Jun 2024 to 30 Apr 2027
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Ease of Use | 10% | quality | — |
| Security of Supply | 15% | quality | — |
| — | 75% | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 33 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 23 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII | £1 | cancelled |
| 2 | CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII | £1 | cancelled |
| 3 | CM/PHS/22/5661/03 Emicizumab | £1 | cancelled |
| 4 | CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) | £1 | cancelled |
| 5 | CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) | £1 | cancelled |